ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review

Chen, Jixin; Chen, Shuqi; Luo, Huiyan; Long, Shunqin; Yang, Xiaobing; He, Wenfeng; Wu, Wanyin*; Wang, Sumei*广东省人民医院; 广州中医药大学; 1
International Immunopharmacology2023-11DOI: 10.1016/j.intimp.2023.110919
1被引7阅读
引用收藏
分享

摘要

Background: Conflicting results about the effect of concomitant medications on immunotherapy in non-small cell lung cancer (NSCLC) were reported by many meta-analyses (MAs), and the certainty of evidence linking concomitant medications with immunotherapy efficacy has not been quantified, which may cause some evidence to be misinterpreted.Methods: Four databases including Embase, Cochrane Library, PubMed, and Web of Science were searched from inception to January 2023 in English. Based on prospective or retrospective clinical controlled trials including immunotherapy with concomitant medications or not in NSCLC, quantitative MAs reporting the efficacy of immunotherapy with binary direct comparison and enough extractable data were collected. The methodological quality, reporting quality, and risk of bias of included MAs were evaluated respectively. New meta-analyses were conducted and their evidence certainty was classified as nonsignificant, weak, suggestive, highly suggestive, or convincing.Results: Fifteen MAs with 5 medications were included. After being assessed by AMSTAR-2, PRISMA, and ROBIS, the major shortcomings were focused on the registration of protocol, literature retrieval or data extraction, implementation of sensitivity analysis or evidence certainty assessment, and incomplete reporting in the section of method and result. New pooled analyses indicated that antibiotics (HR = 1.545[1.318-1.811]), steroids (HR = 1.784[1.520-2.093]), proton pump inhibitors (PPIs) (HR = 1.303[1.048-1.621]) and opioids (HR = 1.910 [1.213-3.006]) could shorten overall survival (OS) in patients with NSCLC receiving immunotherapy. Besides, antibiotics (HR = 1.285[1.129-1.462]) and steroids (HR = 1.613[1.315-1.979]) were harmful to progression-free survival (PFS) in these patients significantly. No negative effect was found in nonsteroidal anti-inflammatory drugs and the objective response rate of all medications. High-level evidence suggested that using PPIs before or after the initiation of immunotherapy and using steroids during the first-course immuno-therapy could weaken the OS of patients with NSCLC. Meanwhile, the negative effects of antibiotics and opioids on OS or PFS were only supported by moderate or low-level evidence. Conclusions: The concurrent usage of PPIs or steroids adversely affects the survival of patients with NSCLC receiving immunotherapy. Future investigations are required to ascertain whether these adverse effects are primarily attributed to the comorbidities or the concurrent medications.

学科与关键词

关键词
ImmunotherapyConcomitant medicationsNSCLCUmbrella reviewPD-1/PD-L1 inhibitor
相关
加载中…
  • Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
    Jiang, Shuai; Geng, Shuai; Chen, Qian; Zhang, Chen; Cheng, Mengfei; Yu, Yang; Zhang, Shuo; Shi, Ning*; Dong, Mei*Frontiers in Oncology, 2022, 12: 823705.被引 15
  • Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs
    Yu, Jiuhang; Yin, Yichuang; Yu, Yang; Cheng, Mengfei; Zhang, Shuo; Jiang, Shuai*; Dong, Mei*Immunopharmacology and Immunotoxicology, 2023, 45(3): 386-394.被引 3
  • Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art
    Kang, Jin; Zhang, Chao; Zhong, Wen-Zhao*Cancer Communications, 2021, 41(4): 287-302.被引 62
查看全部 →

发表信息

论文状态
公开发表
期刊
International Immunopharmacology
发表日期
2023-11
卷期
第 124 卷
页码
110919
DOI
10.1016/j.intimp.2023.110919
语言
ENGLISH
成果收录
SCIE
资助标注
Research Fund for Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine (China) [BJ2022KY13]; Natural Science Founda-tion of Guangdong Province (China) [2021A1515410007, 2021A1515220023, 2017B030314166]; Scientific Research Project in Universities of Guangdong Provincial Department of Educa-tion (China) [2020KTSCX029]

作者

  • C

    Chen, Jixin (第一作者)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • C

    Chen, Shuqi

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 8 位作者收起作者
  • L

    Luo, Huiyan

    1 · guangzhou univ chinese med

  • L

    Long, Shunqin

    guangdong prov hosp · guangzhou univ chinese med

  • Y

    Yang, Xiaobing

    guangdong prov hosp · guangzhou univ chinese med

  • H

    He, Wenfeng

    guangdong prov hosp · guangzhou univ chinese med

  • W

    Wu, Wanyin (通讯)

    guangdong prov hosp · guangzhou univ chinese med · 2 · guangdong prov acad chinese med sci

  • W

    Wang, Sumei (通讯)

    guangdong prov hosp · guangzhou univ chinese med · 2 · guangdong prov acad chinese med sci

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417